How profitable is BGM Group Ltd. (Class A) (BGM)?

In FY 2025 (10-K), BGM converted $37.9M of revenue into a 16.6% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / BGM / financials

CATX (33) FHTX (18) OGI (45) HURA (32) ⌘ Pro Terminal →

BGM Group Ltd. (Class A) (BGM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$9.54 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.52

BGM Group Ltd. (Class A) (BGM) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $127.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BGM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BGM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, BGM Group Ltd. (Class A) (NASDAQ: BGM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $9.54 (0.00% 1D, market cap $127.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BGM ranks #537 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BGM compare to CATX and FHTX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BGM carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 16.6%, and ROIC of —. By comparison, CATX (Perspective Therapeutics Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $131.3M) and FHTX (Foghorn Therapeutics Inc.) posts a E grade (18/100 RQD, P/E N/A, ROIC -35.0%, cap $123.5M). Among the 5-stock peer group, BGM leads on earnings multiple (N/A) while CATX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BGM?

▼

Per BGM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001779578), BGM Group Ltd. (Class A) generated $37.9M in revenue (+51.1% YoY), -$19.9M in net income, and -$3.9M in free cash flow against $433.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.52 (-0.19%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-9.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BGM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY BGM SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+12/20 pts (32% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 16.6% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (24% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$10.20-12.1% Next Q

Q2 (-2Q)

Grade D$8.97-6.4% Next Q

Q3 (-1Q)

Grade D$8.40+13.6% Next Q

Current

Grade D-$9.54-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BGM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BGM currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.54) and Max Pain ($10.02) forces dealer call-delta covering toward $317.52.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BGM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BGM Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How BGM Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $46.5M

FY24

Rev $25.1M

FY25

Rev $37.9M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$37.9M	16.6%	-33.2%	-$19.9M	-$3.9M	15%
FY 2024	$25.1M	16.4%	-2.2%	-$1.4M	$304.1K	15%
FY 2023	$46.5M	16.6%	-5.6%	-$7.8M	$312.2K	15%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BGM)

✓Walkthrough of BGM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BGM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -0.63%▼ DESCENDING CHANNEL

2026-11-03O $9.54H $9.54L $9.54C $9.54VOL 299

RES: $10.53SUP: $6.11SMA50: $8.54SMA200: $18.72

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BGM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BGM Butterfly Map → + Track BGM →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +51.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BGM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BGM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BGM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BGM)

Health Care Rank #537 of 1015 ⚔️ CATX vs BGM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BGM vs. CATX, FHTX, OGI, HURA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, BGM Group Ltd. (Class A) (BGM) ranks #537 by composite RQD confidence (37/100, grade D-) and #626 by equity capitalization ($127.4M). Within this direct 5-issuer industry benchmark cohort, BGM leads on earnings valuation at N/A trailing P/E, while CATX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OGI currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with BGM at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BGM ACTIVE BGM Group Ltd. (Class A)	D-	37/100	—	16.6%	—	0.00%	$127.4M	Benchmark Subject
CATX Perspective Therapeutics Inc.	E	33/100	—	—	-35.0%	-9.56%	$131.3M	/catx-vs-bgm →
FHTX Foghorn Therapeutics Inc.	E	18/100	—	—	-35.0%	+2.40%	$123.5M	/fhtx-vs-bgm →
OGI Organigram Global Inc.	D	45/100	—	—	—	+3.43%	$131.6M	/ogi-vs-bgm →
HURA TuHURA Biosciences Inc.	E	32/100	—	—	-35.0%	-10.88%	$123.0M	/hura-vs-bgm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001779578 ↗

In its most recent audited fiscal period (FY2025, filed 2025-09-30), BGM Group Ltd. (Class A) (BGM) reported GAAP revenue of $37.9M (+51.1% vs. FY2024 revenue of $25.1M , and -18.4% cumulative change since FY2023) , GAAP net income of -$19.9M, operating cash flow of -$2.4M, and free cash flow of -$3.9M (-1395.3% YoY). On the balance sheet, BGM closed FY2025 with $433.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$37.9M	-$19.9M	-$2.4M	-$3.9M	$433.8M	—
FY2024 (FY)	2024-09-30	$25.1M	-$1.4M	$544.2K	$304.1K	—	—
FY2023 (FY)	2023-09-30	$46.5M	-$7.8M	$312.2K	$312.2K	—	—

3. BGM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BGM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BGM compare to CATX and FHTX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BGM?

Where is BGM trading relative to its 50-day, 200-day, and 52-week technical levels?

BGM last traded at $9.54 (0.00% on volume of 748 shares), positioning the stock +11.71% above its 50-day simple moving average ($8.54) and -49.04% below its 200-day simple moving average ($18.72). Across its 52-week range of $6.45 to $302.40, BGM sits at the 1.0% percentile with a 14-day RSI of 56.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($8.35 to $10.73).

Direct Sub-Reports: BGM RQD Cockpit BGM 12M Forecast BGM Earnings & Move BGM Dividends & DRIP BGM Insiders & 13F BGM Whale Options BGM Profit Sankey BGM News & Why

ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

BGM — BGM Group Ltd. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-09-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

BGM Group Ltd. (Class A) (BGM) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $9.54 (0.00% 1D, market capitalization $127.4M).

Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of 16.6%, operating margin of -33.2%, and free cash flow yield of -3.09%.
Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (5/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

BGM Group Ltd. (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company reported revenue of $37.9M for FY 2025, indicating an operating business with meaningful top-line activity. Operating and net margins are negative, per the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), BGM Group Ltd. (Class A) (BGM) reported $37.9M in annual revenue (up from $25.1M in FY2024, +51.1% YoY) and -$19.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($46.5M revenue, -$7.8M net income) through FY2025, BGM scaled operating cash flow to -$2.4M and free cash flow to -$3.9M, backed by $433.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.09% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $6.45 – $302.40 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -33.2% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The sector is Health Care and the industry is Biotechnology: Pharmaceutical Preparations, but no linkage to specific suppliers, customers, or peers is provided.

Key Question #1: Can BGM sustain or expand its -33.2% operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $37.9M and free cash flow of -$3.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is BGM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BGM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BGM Group Ltd. (Class A) (BGM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BGM Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

BGM Strengthens the Firm's Northeast Presence

Yahoo Finance report covering BGM Group Ltd. (Class A) (BGM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH kalkine.ca • 1d ago

Why Is BGM Group (NASDAQ:BGM) Stock Down 8% Today, and What Are Investors Missing After a Run of Trading Halts?

kalkine.ca report covering BGM Group Ltd. (Class A) (BGM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

Responsive Playbooks and the BGM Inflection

Stock Traders Daily report covering BGM Group Ltd. (Class A) (BGM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE NFHS Network • 1d ago

Team Highlights: Varsity Football BGM Community High School vs. Martensdale-St Marys Jr/Sr High School - BGM

NFHS Network report covering BGM Group Ltd. (Class A) (BGM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Promising Chinese Stocks To Watch Today - October 5th

MarketBeat report covering BGM Group Ltd. (Class A) (BGM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Top U.S. Stock Losers: Biggest Price Declines

TradingKey report covering BGM Group Ltd. (Class A) (BGM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Cinema Express • 2d ago

Jailer 2: Hrithik Roshan acknowledges cameo in Rajinikanth starrer, drops his character BGM

Cinema Express report covering BGM Group Ltd. (Class A) (BGM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 2d ago

Qilian International Holding Group Limited (NASDAQ: BGM) Stock Price, News & Analysis

kalkine.ca report covering BGM Group Ltd. (Class A) (BGM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BGM Bull vs. Bear Conversation Board — What's Your Call at $9.54?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BGM 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $12.50 (+31.0%)

📌 Pinned Debate

Revenue grew from $25.1M in FY 2024 to $37.9M in FY 2025 while the stock sits near the bottom of its 52-week range at $9.54.

Don't sleep on BGM's setup in Health Care. Revenue grew from $25.1M in FY 2024 to $37.9M in FY 2025 while the stock sits near the bottom of its 52-week range at $9.54.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (37/100) backs up the fundamental quality.

ArenaChamp_24 🐂 BULL

@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (16.6%) holds, EPS grows into the multiple faster than bears think.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $8.11 (-15.0%)

Spot @ $9.54

Net margin of -52.6%, ROIC of 0%, and Piotroski F-Score of 2 of 9 show weak profitability and financial quality.

Here is the bear case nobody on the bull side wants to address on BGM: Net margin of -52.6%, ROIC of 0%, and Piotroski F-Score of 2 of 9 show weak profitability and financial quality.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.